Interestingly, we uncovered enriched classes such as DNA Topoisomerase and Sphingosine Kinase (SphK) inhibitors which, to the best of our knowledge, have not been previously identified as possible therapeutic options for ADPKD. The gene discussed is SPHK1; the disease is autosomal dominant polycystic kidney disease.